OS Data
-
- The following claim "ArradiCAN demonstrated superior OS compared with chemotherapy: 24% reduction in death (p = 0.06)" is inconsistent with the data presented in the TMA. Please revise the claim based on the data from the PM, or direct our eyes to an updated reference. (s. 4.1, 4.2)
a) The figure is not representative of the data referenced within the PM. Furthermore, we question the axes titles. Please revise or direct our eyes to an updated reference. (s. 4.1.1, 4.1.2)
b) We question the accuracy of the downward arrow stating "24%". Please revise or direct our eyes to an updated reference. (s. 4.1)
c) We question the side callout "254 of patients treated with ArradiCAN" as the copy deck does not align with the layout and appears to be incomplete. Please revise.